Madrigal's Trading Volume Surges 97.53% to 2.78 Billion, Ranks 362nd Despite Stock Price Decline

On May 1, 2025, Madrigal's trading volume reached 2.78 billion, marking a significant increase of 97.53% compared to the previous day. This surge placed Madrigal at the 362nd position in the day's stock market rankings. However, the stock price of Madrigal (MDGL) has been on a downward trend, falling by 1.86% and marking its second consecutive day of decline, with a total decrease of 3.84% over the past two days.

Madrigal Pharmaceuticals, Inc. announced that it has entered into a definitive agreement to acquire Resverlogix Corp. The acquisition is expected to enhance Madrigal's pipeline and strengthen its position in the cardiovascular disease market. The transaction is subject to customary closing conditions and is anticipated to be completed in the third quarter of 2025.

Madrigal Pharmaceuticals, Inc. has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for resmetirom. The FDA has requested additional data to support the efficacy and safety of the drug. Madrigal plans to work closely with the FDA to address the concerns and resubmit the NDA as soon as possible.

Madrigal Pharmaceuticals, Inc. has announced the initiation of a Phase 3 clinical trial for its lead drug candidate, resmetirom, in patients with non-alcoholic steatohepatitis (NASH). The trial is designed to evaluate the efficacy and safety of resmetirom in improving liver histology and reducing cardiovascular risk factors in NASH patients. The company expects to enroll approximately 1,500 patients across multiple sites in the United States and Europe.